GlassScriptPhysician profile
David P Law
NPI 1770690604
$1,179.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $486.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $333.85 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $224.05 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $195.95 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $108.35 | 2021-2022 | |
| Indivior INC. | $86.29 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $66.27 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.22 | 2021 | |
| Abbvie INC. | $39.17 | 2022 | |
| Lundbeck LLC | $29.81 | 2021-2022 | |
| Noven Therapeutics, LLC | $28.03 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.22 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.